A Multicenter, Open, Prospective Study of Prognostic Value and Benefit From Adjuvant Immunotherapy of Stage III Papillary Renal Cell Carcinoma Based on Multi-classifier System
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 468
- 主要终点
- Disease-free survival
研究概览
简要总结
The goal of this trial is to test whether patients with stage III papillary renal cell carcinoma (pRCC) could benefit from adjuvant therapy or not. The investigators invented a multi-classifier system that was successfully categorise patients with stage III pRCC into high-risk and low-risk groups. Here the investigators randomly assign classifier-defined high risk patients of stage III pRCC into adjuvant pembrolizumab group placebo group. Disease-free survival and overall survival are the end points of observation.
详细描述
kidney cancer represented 4.2% of all new cancer cases, and its incidence has been increasing. Over 90% of kidney cancer cases are renal cell carcinoma (RCC), which includes various subtypes with distinct histologic features, clinical courses, and responses to therapy. Clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) are the most common histologic subtypes of RCC, accounting for approximately 75% and 20% of all cases, respectively. Adjuvant pembrolizumab showed promising efficacy in ccRCC, however, whether high-risk pRCC patients could benefit from adjuvant pembrolizumab remain unknown.
Participants will be assigned to continue with the study treatment until any of the following occurs: the recurrence of the disease; the emergence of unacceptable adverse events (AEs); the presence of an intercurrent illness that precludes further administration of the treatment; the decision of the Investigator to withdraw the participant; noncompliance with the study treatment or procedural mandates; administrative reasons necessitating the discontinuation of treatment; or the completion of 17 treatment cycles (approximately one year), with each cycle 3 weeks long.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological confirmation of pRCC
- •With confirmed diagnosis of stage III pRCC
- •Classified as high-risk by multi-classifier system
- •With moderate/good Eastern Cooperative Oncology Group (ECOG) health rating (PS): 0-1 score.
- •Receive radical operation for renal cancer with negative margin.
- •Receive no anti-cancer treatment before primary surgery.
- •The informed consent has been obtained from the patient.
排除标准
- •Patients with Transcription factor enhancer 3(TFE3) or transcription factor EB (TFEB) translocation proven by cytogenetic analysis or by fluorescence in situ hybridization (FISH)
- •Previously received neoadjuvant therapy
- •With severe comorbidities, such as cardiovascular disease, chronic obstructive pulmonary disease, diabetes mellitus, and chronic renal dysfunction.
- •With bad compliance or contraindication to enrollment.
- •Pregnant woman or lactating woman.
- •With contraindication to receive pembrolizumab, such as had a prior solid organ transplant, has a known history of human immunodeficiency virus infection.
研究组 & 干预措施
Pembrolizumab
Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for up to 17 cycles.
干预措施: Pembrolizumab (Drug)
Placebo
Participants receive intravenous placebo on Day 1 of each 3-week cycle for up to 17 cycles.
干预措施: Placebo (Drug)
结局指标
主要结局
Disease-free survival
时间窗: From the date of registration to up to 7 years
Disease free survival (DFS) was defined as the time interval (in years) from the date of randomization to the first date of recurrence or occurrence of a secondary malignancy or death.
次要结局
- Overall survival(From the date of registration to up to 7 years)
研究者
Jun-Hang Luo
Professor
First Affiliated Hospital, Sun Yat-Sen University